Suspended
Camrelizumab Combined With Chemotherapy and Local Treatment in Non-small Cell Lung Cancer Patients With Brain Metastasis, a Single-arm, Multi-center, Open-labeled Phase II Clinical Trial
What is being tested
Immunotherapy
+ WBRT
+ Chemotherapy
DrugRadiation
Who is being recruted
Brain Diseases+13
+ Brain Neoplasms
+ Bronchial Neoplasms
Over 18 Years
+18 Eligibility Criteria
How is the trial designed
Treatment Study
Phase 2
Interventional
Study Start: January 2020
Summary
Principal SponsorZhejiang Cancer Hospital
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: January 1, 2020
Actual date on which the first participant was enrolled.To evaluate the efficacy and safety of Camrelizumab Combined with Chemotherapy and Local Treatment of brain metastases (WBRT, r-knife, SRS, etc.) in non-small cell lung cancer patients with brain metastases .
Official TitleCamrelizumab Combined With Chemotherapy and Local Treatment in Non-small Cell Lung Cancer Patients With Brain Metastasis, a Single-arm, Multi-center, Open-labeled Phase II Clinical Trial
Principal SponsorZhejiang Cancer Hospital
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
63 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Brain DiseasesBrain NeoplasmsBronchial NeoplasmsCarcinoma, BronchogenicCarcinoma, Non-Small-Cell LungCentral Nervous System DiseasesLung DiseasesLung NeoplasmsNeoplasmsNeoplasms by SiteNervous System DiseasesNervous System NeoplasmsRespiratory Tract DiseasesRespiratory Tract NeoplasmsThoracic NeoplasmsCentral Nervous System Neoplasms
Criteria
6 inclusion criteria required to participate
Age ≥18;
ECOG is 0-1;
Non-small cell lung cancer confirmed by histology; EGFR、ALK and ROS1 negative;
The presence of brain metastases as determined by imaging, with unlimited numbers, the intracranial lesions had a maximum diameter of ≥ 0.5cm，allowing the presence of clinical symptoms of brain metastases;
Show More Criteria
12 exclusion criteria prevent from participating
Immunotherapeutic contraindications (including long-term use of hormones, history of radiation pneumonia, etc.)
Active autoimmune diseases (e.g. vitiligo, psoriasis, hypothyroidism requiring hormone replacement therapy, etc.)
Patients with active hepatitis B or C, HIV, active tuberculosis, etc.;
Active infections requiring antimicrobial therapy (e.g. antimicrobial, antiviral, antifungal);
Show More Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Treatment Groups
Study Objectives
One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
Experimentalsingle-arm
Study Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Recruiting
SuspendedOne Study Center